CYCCP Cyclacel Pharmaceuticals, Inc.

Nasdaq cyclacel.com


$ 5.04 $ -0.23 (-4.36 %)    

Thursday, 11-Sep-2025 15:01:44 EDT
QQQ $ 606.22 $ 2.41 (0.4 %)
DIA $ 465.67 $ 1.17 (0.25 %)
SPY $ 669.03 $ 2.26 (0.34 %)
TLT $ 91.07 $ 0.11 (0.13 %)
GLD $ 386.59 $ 0.65 (0.17 %)
$ 5.05
$ 5.35
$ 4.70 x 425
$ 5.70 x 200
-- - --
$ 3.10 - $ 16.00
6,463
na
13.14M
$ 0.48
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 04-02-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 03-21-2024 12-31-2023 10-K
8 11-29-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-08-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-30-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-14-2021 03-31-2021 10-Q
19 03-01-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-13-2020 06-30-2020 10-Q
22 05-12-2020 03-31-2020 10-Q
23 03-05-2020 12-31-2019 10-K
24 11-13-2019 09-30-2019 10-Q
25 08-13-2019 06-30-2019 10-Q
26 05-14-2019 03-31-2019 10-Q
27 03-28-2019 12-31-2018 10-K
28 11-13-2018 09-30-2018 10-Q
29 08-09-2018 06-30-2018 10-Q
30 05-14-2018 03-31-2018 10-Q
31 03-30-2018 12-31-2017 10-K
32 11-13-2017 09-30-2017 10-Q
33 08-10-2017 06-30-2017 10-Q
34 05-12-2017 03-31-2017 10-Q
35 03-31-2017 12-31-2016 10-K
36 11-14-2016 09-30-2016 10-Q
37 08-11-2016 06-30-2016 10-Q
38 05-13-2016 03-31-2016 10-Q
39 03-29-2016 12-31-2015 10-K
40 11-12-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, "Cyclacel" or the "Company"))), a biopharmaceutical ...

Core News & Articles

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, "Cyclacel" or the "Company"))) today announced that ...

Core News & Articles

Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ:CYCC, NASDAQ:CYCCP), a biopharmaceutical company that develops inno...

Core News & Articles

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", ))), a biopharmace...

Core News & Articles

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", ))), a biopharmace...

Core News & Articles

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )))), a biopharmac...

Core News & Articles

 - Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action -BERKELEY HEIGH...

Core News & Articles

- Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of concept study i...

Core News & Articles

- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program ...

Core News & Articles

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )))), a biopharmac...

Core News & Articles

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )))), a biopharmac...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION